Chimeric monoclonal anti-CD20 antibody (rituximab) - an effective treatment for a patient with relapsing hairy cell leukaemia

被引：19

作者：

Hagberg, H ^{[1
]}

机构：

[1] Univ Uppsala, Akad Sjukhuset, Dept Oncol, S-75185 Uppsala, Sweden

来源：

MEDICAL ONCOLOGY | 1999年 / 16卷 / 03期

关键词：

hairy cell leukaemia; anti CD-20 antibodies; rituximab;

D O I：

10.1007/BF02906136

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A case story is presented, describing a 46 y old man, with a relapsing hairy cell leukaemia. After treatment with monoclonal anti CD-20 antibodies (rituximab) 375 mg/week, four times, a complete remission was obtained which has lasted >9 months. The rituximab treatment produced a better remission than earlier treatments with alpha-interferon and chlorodeoxyadenosine. In addition, in contrast to other treatments, no initial worsening of the pancytopenia was observed.

引用

页码：221 / 222

页数：2

共 2 条

[1] Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: A report of 979 patients [J].

Cheson, BD ;

Sorensen, JM ;

Vena, DA ;

Montello, MJ ;

Barret, JA ;

Damasio, E ;

Tallman, M ;

Annino, L ;

Conners, J ;

Coiffier, B ;

Lauria, F .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) :3007-3015

[2] Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:: Half of patients respond to a four-dose treatment program [J].

McLaughlin, P ;

Grillo-López, AJ ;

Link, BK ;

Levy, R ;

Czuczman, MS ;

Williams, ME ;

Heyman, MR ;

Bence-Bruckler, I ;

White, CA ;

Cabanillas, F ;

Jain, V ;

Ho, AD ;

Lister, J ;

Wey, K ;

Shen, D ;

Dallaire, BK .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2825-2833

← 1 →